Benzinga | Aug 4, 2021 05:05PM EDT

10x Genomics Q2 EPS $(0.10) Beats $(0.26) Estimate, Sales $115.85M Beat $112.85M Estimate; Reaffirms FY21 Sales Guidance $480M-$500M vs $496.5M Est.

10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.26) by 61.54 percent. This is a 75.61 percent increase over losses of $(0.41) per share from the same period last year. The company reported quarterly sales of $115.85 million which beat the analyst consensus estimate of $112.85 million by 2.66 percent. This is a 170.02 percent increase over sales of $42.91 million the same period last year.